Clinical Trial Results:
            GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary breast cancer.
 A joint study of GBG and AGO
    
|     Summary | |
|     EudraCT number | 2005-001546-17 | 
|     Trial protocol | DE | 
|     Global completion date | 
                                    01 Aug 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    09 Sep 2021
                             | 
|     First version publication date | 
                                    09 Sep 2021
                             | 
|     Other versions | |
|     Summary report(s) | CSR Synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
